Income Statement
HALOZYME THERAPEUTICS, INC.
HALO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
1,396.61 | 1,015.32 | 829.25 | 660.12 | 443.31 | 267.59 | 195.99 | 151.86 | 316.61 | 146.69 | 135.06 | 75.33 | 54.80 | 42.33 | 56.09 |
|
Cost of Revenue
|
228.77 | 159.42 | 192.36 | 139.30 | 81.41 | 43.37 | 45.55 | - | - | - | - | - | - | - | - |
|
Gross Profit
|
1,167.84 | 855.91 | 636.89 | 520.81 | 361.90 | 224.23 | 150.45 | 151.86 | 316.61 | 146.69 | 135.06 | 75.33 | 54.80 | 42.33 | 56.09 |
|
Operating Expenses
|
207.09 | 233.38 | 225.55 | 210.13 | 86.00 | 79.97 | 218.06 | 211.06 | 204.46 | 196.70 | 133.26 | 115.64 | 128.99 | 94.86 | 75.67 |
|
Research & Development
|
81.49 | 79.05 | 76.36 | 66.61 | 35.67 | 34.24 | 140.80 | 150.25 | 150.64 | 150.84 | 93.24 | 79.70 | 96.64 | 70.04 | 57.56 |
|
Selling, General & Administrative
|
207.09 | 154.34 | 149.18 | 143.53 | 50.32 | 45.74 | 77.25 | 60.80 | 53.82 | 45.85 | 40.03 | 35.94 | 32.35 | 24.81 | 18.10 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
960.75 | 622.52 | 411.35 | 310.68 | 275.90 | 144.26 | -67.61 | -59.19 | 112.15 | -50.00 | 1.79 | -40.30 | -74.19 | -52.53 | -19.58 |
|
Non-Operating Income
|
493.87 | 65.39 | 63.02 | 61.76 | 27.38 | 14.95 | 4.64 | 20.60 | 50.54 | 51.86 | - | - | - | - | - |
|
Interest Income
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
16.26 | 15.76 | 18.76 | 16.95 | 7.53 | 20.38 | 11.63 | 18.04 | 21.98 | 20.00 | 5.20 | 5.60 | 3.30 | 0.03 | - |
|
Other Non-Op Income / Expense
|
21.47 | 23.75 | 16.32 | 1.05 | 1.10 | 5.43 | 6.99 | 7.58 | 2.59 | - | - | - | - | 0.07 | 0.07 |
|
Income Before Tax
|
466.88 | 557.13 | 348.33 | 248.92 | 248.52 | 129.30 | -72.25 | -79.79 | 61.61 | -101.86 | - | - | - | - | - |
|
Income Tax Expense
|
149.99 | 113.04 | 66.74 | 46.79 | -154.19 | 0.22 | -0.01 | 0.54 | -1.36 | 1.16 | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
316.89 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | -72.24 | -80.33 | 62.97 | -103.02 | -32.23 | -68.38 | -83.48 | -53.55 | -19.77 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
972.15 | 632.82 | 422.45 | 317.18 | 278.90 | 147.56 | -63.51 | -56.79 | 114.35 | -47.59 | 3.47 | -38.54 | -72.96 | -51.45 | -18.49 |
|
Earnings Per Share (Basic)
|
2.64 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | - | -0.56 | 0.46 | - | - | - | - | - | - |
|
Diluted EPS
|
2.56 | 3.43 | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 | -0.56 | 0.45 | - | - | - | - | - | - |
|
Weighted Average Shares
|
119.84 | 126.83 | 131.93 | 136.84 | 140.65 | 136.21 | 144.33 | 143.60 | 136.42 | - | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
123.90 | 129.42 | 134.20 | 140.61 | 146.80 | 141.46 | 144.33 | 143.60 | 139.07 | - | - | - | - | - | - |
|
Comprehensive Income
|
294.97 | 457.20 | 273.24 | 201.83 | 402.07 | 128.87 | -71.72 | -80.16 | 62.53 | -102.93 | -32.29 | -68.43 | -83.46 | -53.55 | - |